|
25.02.2016 18:10:00
|
AMAG Pharmaceuticals, Inc. -- Moody's: AMAG's Single Dose, Preservative Free Makena approval by the FDA is credit positive; ratings unaffected
New York, February 25, 2016 -- Moody's Investors Service commented that the FDA's approval of AMAG's single-dose, preservative-free formulation for Makena (hydroxyprogesterone caproate injection) is credit positive. However there is no effect on AMAG's current B2 Corporate Family Rating. The rating outlook is positive.
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.